NCT03001193

Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Effect of Continuous Infusion of Tafoxiparin as an Adjunct Treatment to Oxytocin for up to 36 Hours in Term Pregnant, Nulliparous Women to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 361 (actual)
• Sponsor: Dilafor AB · Industry
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The study will be designed as a double-blind, placebo-controlled, parallel-group, dose-finding study with one group treated with placebo and three groups treated with tafoxiparin in three different infusion concentration levels, respectively. The intravenous infusion will be initiated by a pre-defined bolus dose infusion.

Detailed description

Primary objective To assess the dose-response relationship of tafoxiparin on the labor time defined as the time from the start of continuous infusion of tafoxiparin/placebo as an Adjunct Treatment to Oxytocin, until partus in term-pregnant, nulliparous women requiring labor augmentation due to Primary Slow Progress of Labor including prolonged latent phase and Labor Arrest. Secondary objectives To assess the safety and efficacy of tafoxiparin based on the safety and secondary efficacy parameters evaluated in the protocol. PK (pharmacokinetic) response in pregnant women during labor. Methodology All term-pregnant, nulliparous women presenting to the delivery ward are potential study patients unless they have already been enrolled in another clinical study. Subjects may be pre-informed about the study through the use of advertisements or information at the physician/midwife visits during pregnancy and at hospital admission. The whole study includes the following steps: * Screening and Baseline including informed consent and randomization * Labor * Discharge * Follow-up at 8 (+/-1)weeks - End of study * Safety follow up of infant at 6 months, +/-4 weeks, by telephone interview

Conditions

• Labor, Obstetric

Interventions

Type	Name	Description
DRUG	DF 01
DRUG	Oxytocin
DRUG	Placebo

Timeline

• Start date: 2016-12-01
• Primary completion: 2018-11-01
• Completion: 2019-05-01
• First posted: 2016-12-22
• Last updated: 2020-04-29

Locations

12 sites across 3 countries: Denmark, Finland, Sweden